RHYTHM PHARMACEUTICALS INC

For the period ended Mar 31, 2024. Filed May 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 7, 2024

RYTM$113.94+1.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)


· · March 31, · · December 31,
	2024		2023

Assets
Current assets: · ·
Cash and cash equivalents		$53,428		$60,081
Short-term investments		147,771		215,765
Accounts receivable, net		14,695		14,867
Inventory		8,507		8,624
Prepaid expenses and other current assets		11,352		8,931
Total current assets		235,753		308,268
Property and equipment, net		1,149		1,341
Right-of-use asset		670		781
Intangible assets, net		6,815		7,028
Restricted cash		460		328
Other long-term assets		13,804		14,999
Total assets		$258,651		$332,745
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable		$7,550		$4,885
Accrued expenses and other current liabilities		44,531		48,262
Deferred revenue		1,286		1,286
Lease liability		793		770
Total current liabilities		54,160		55,203
Long-term liabilities:
Deferred royalty obligation		107,368		106,143
Lease liability, non-current		284		490
Derivative liability		660		1,150
Other long-term liabilities		34,598		—
Total liabilities		197,070		162,986
Commitments and contingencies (Note 14)
Stockholders’ equity:
Preferred Stock, $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023		—		—
Common stock, $0.001 par value: 120,000,000 shares authorized; 60,964,468 and 59,426,559 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively		60		59
Additional paid-in capital		1,097,810		1,064,302
Accumulated other comprehensive income (loss)		(181)		134
Accumulated deficit		(1,036,108)		(894,736)
Total stockholders’ equity		61,581		169,759
Total liabilities and stockholders’ equity		$258,651		$332,745

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.